| Source: |
| Type: |
| Power to enhance an anti cancer effect |
| 6216- | CUR, | Role of Turmeric and Curcumin in Prevention and Treatment of Chronic Diseases: Lessons Learned from Clinical Trials |
| - | Review, | Var, | NA |
| 6225- | CUR, | Natural products for enhancing the sensitivity or decreasing the adverse effects of anticancer drugs through regulating the redox balance |
| - | Review, | Var, | NA |
| 6221- | CUR, | Oxidative Stress and Cancer: Harnessing the Therapeutic Potential of Curcumin and Analogues Against Cancer |
| - | Review, | Var, | NA |
| 6209- | CUR, | Curcumin as a complementary treatment in oncological therapy: a systematic review |
| 6408- | CUR, | Protective Effects of a Natural Product, Curcumin, against Amyloid β Induced Mitochondrial and Synaptic Toxicities in Alzheimer'S Disease |
| - | in-vitro, | AD, | SH-SY5Y |
| 2688- | CUR, | Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 2812- | CUR, | Curcumin Induces High Levels of Topoisomerase I− and II−DNA Complexes in K562 Leukemia Cells |
| - | in-vitro, | AML, | K562 |
| 2808- | CUR, | Iron chelation by curcumin suppresses both curcumin-induced autophagy and cell death together with iron overload neoplastic transformation |
| - | in-vitro, | Liver, | HUH7 |
| 2978- | CUR, | N-acetyl cysteine mitigates curcumin-mediated telomerase inhibition through rescuing of Sp1 reduction in A549 cells |
| - | in-vitro, | Lung, | A549 |
| 4830- | CUR, | Curcumin and Its Derivatives Induce Apoptosis in Human Cancer Cells by Mobilizing and Redox Cycling Genomic Copper Ions |
| - | in-vitro, | Var, | NA |
| 4826- | CUR, | The Bright Side of Curcumin: A Narrative Review of Its Therapeutic Potential in Cancer Management |
| - | Review, | Var, | NA |
| 1609- | CUR, | EA, | Curcumin and Ellagic acid synergistically induce ROS generation, DNA damage, p53 accumulation and apoptosis in HeLa cervical carcinoma cells |
| - | in-vitro, | Cerv, | NA |
| 1982- | CUR, | Inhibition of thioredoxin reductase by curcumin analogs |
| - | in-vitro, | NA, | NA |
| 1981- | CUR, | Mitochondrial targeted curcumin exhibits anticancer effects through disruption of mitochondrial redox and modulation of TrxR2 activity |
| - | in-vitro, | Lung, | NA |
| 1979- | CUR, | Rad, | Dimethoxycurcumin, a metabolically stable analogue of curcumin enhances the radiosensitivity of cancer cells: Possible involvement of ROS and thioredoxin reductase |
| - | in-vitro, | Lung, | A549 |
| 1978- | CUR, | Curcumin targeting the thioredoxin system elevates oxidative stress in HeLa cells |
| - | in-vitro, | Cerv, | HeLa |
| 1977- | CUR, | Synthesis and evaluation of curcumin analogues as potential thioredoxin reductase inhibitors |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Lung, | A549 |
| 1409- | CUR, | Curcumin analog WZ26 induces ROS and cell death via inhibition of STAT3 in cholangiocarcinoma |
| - | in-vivo, | CCA, | Walker256 |
| 1510- | CUR, | Chemo, | Combination therapy in combating cancer |
| - | Review, | NA, | NA |
| 3583- | CUR, | Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers |
| - | Review, | Arthritis, | NA |
| 3588- | CUR, | The effect of curcumin on cognition in Alzheimer’s disease and healthy aging: A systematic review of pre-clinical and clinical studies |
| - | Review, | AD, | NA |
| 3582- | CUR, | PI, | Therapeutic and Preventive Effects of Piperine and its Combination with Curcumin as a Bioenhancer Against Aluminum-Induced Damage in the Astrocyte Cells |
| 3579- | CUR, | AgNPs, | Metal–Curcumin Complexes in Therapeutics: An Approach to Enhance Pharmacological Effects of Curcumin |
| - | Review, | NA, | NA |
| 3578- | CUR, | SIL, | Curcumin, but not its degradation products, in combination with silibinin is primarily responsible for the inhibition of colon cancer cell proliferation |
| - | in-vitro, | CRC, | DLD1 |
| 3574- | CUR, | The effect of curcumin (turmeric) on Alzheimer's disease: An overview |
| - | Review, | AD, | NA |
| 410- | CUR, | Nrf2 depletion enhanced curcumin therapy effect in gastric cancer by inducing the excessive accumulation of ROS |
| - | vitro+vivo, | GC, | AGS | - | vitro+vivo, | GC, | HGC27 |
| 135- | CUR, | Curcumin induces apoptosis and protective autophagy in castration-resistant prostate cancer cells through iron chelation |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 143- | CUR, | Nonautophagic cytoplasmic vacuolation death induction in human PC-3M prostate cancer by curcumin through reactive oxygen species -mediated endoplasmic reticulum stress |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 117- | CUR, | Increased Intracellular Reactive Oxygen Species Mediates the Anti-Cancer Effects of WZ35 via Activating Mitochondrial Apoptosis Pathway in Prostate Cancer Cells |
| - | in-vivo, | Pca, | RM-1 | - | in-vivo, | Pca, | DU145 |
| 118- | CUR, | Curcumin analog WZ35 induced cell death via ROS-dependent ER stress and G2/M cell cycle arrest in human prostate cancer cells |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | DU145 |
| 134- | CUR, | RES, | MEL, | SIL, | Thioredoxin 1 modulates apoptosis induced by bioactive compounds in prostate cancer cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 |
| 129- | CUR, | Curcumin suppressed the prostate cancer by inhibiting JNK pathways via epigenetic regulation |
| - | vitro+vivo, | Pca, | LNCaP |
| 130- | CUR, | Maspin Enhances the Anticancer Activity of Curcumin in Hormone-refractory Prostate Cancer Cells |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 14- | CUR, | Curcumin, a Dietary Component, Has Anticancer, Chemosensitization, and Radiosensitization Effects by Down-regulating the MDM2 Oncogene through the PI3K/mTOR/ETS2 Pathway |
| - | vitro+vivo, | Pca, | PC3 |
| 12- | CUR, | Curcumin inhibits the Sonic Hedgehog signaling pathway and triggers apoptosis in medulloblastoma cells |
| - | in-vitro, | MB, | DAOY |
| 167- | CUR, | Curcumin-induced apoptosis in PC3 prostate carcinoma cells is caspase-independent and involves cellular ceramide accumulation and damage to mitochondria |
| - | in-vitro, | Pca, | PC3 |
| 6238- | CUSP9, | A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3 |
| - | Trial, | GBM, | NA |
| 6236- | CUSP9, | EP, | Tumor Treating Fields (TTFields) combined with the drug repurposing approach CUSP9v3 induce metabolic reprogramming and synergistic anti-glioblastoma activity in vitro |
| - | in-vitro, | GBM, | U251 |
| 6239- | CUSP9, | The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy |
| - | in-vitro, | GBM, | NA |
| 6241- | CUSP9, | RECURRENT GLIOBLASTOMA: INITIAL EXPERIENCES WITH COMPASSIONATE-USE CUSP9v3/v4 |
| - | Trial, | GBM, | NA |
| 6245- | Cyc, | Blockade of Hedgehog Signaling Inhibits Pancreatic Cancer Invasion and Metastases: A New Paradigm for Combination Therapy in Solid Cancers |
| - | vitro+vivo, | PC, | NA |
| 6252- | Cyc, | Hedgehog Pathway Inhibitors as Targeted Cancer Therapy and Strategies to Overcome Drug Resistance |
| - | Review, | Var, | NA |
| 6264- | Cyste, | Different inhibition characteristics of intracellular transglutaminase activity by cystamine and cysteamine |
| - | Review, | Nor, | NA |
| 6262- | Cyste, | A Randomized Controlled Crossover Trial with Delayed-Release Cysteamine Bitartrate in Nephropathic Cystinosis: Effectiveness on White Blood Cell Cystine Levels and Comparison of Safety |
| - | Trial, | Nor, | NA |
| 6261- | Cyste, | A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis |
| 1871- | DAP, | Targeting PDK1 with dichloroacetophenone to inhibit acute myeloid leukemia (AML) cell growth |
| - | in-vitro, | AML, | U937 | - | in-vivo, | AML, | NA |
| 6684- | DAP, | GB, | Pharmacological synergism of 2,2-dichloroacetophenone and EGFR-TKi to overcome TKi-induced resistance in NSCLC cells |
| - | vitro+vivo, | NSCLC, | H1975 |
| 6593- | DAS, | Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors |
| 6591- | DAS, | Dasatinib in solid tumors |
| - | Review, | Var, | NA |
| 6683- | DCA, | Dichloroacetate for Cancer Treatment: Some Facts and Many Doubts |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:961 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid